These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
(State or other jurisdiction of Incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
Large accelerated filer
|
☐
|
|
☑
|
|
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
|
|
|
Emerging growth company
|
|
|
|
Page No.
|
|||
|
PART I—FINANCIAL INFORMATION
|
||||
|
ITEM 1
|
Financial Statements (Unaudited)
|
|||
|
5
|
||||
|
6
|
||||
|
7
|
||||
|
8
|
||||
|
9
|
||||
|
10
|
||||
|
11
|
||||
|
ITEM 2
|
34
|
|||
|
ITEM 3
|
47
|
|||
|
ITEM 4
|
47
|
|||
|
PART II—OTHER INFORMATION
|
||||
|
ITEM 1
|
48
|
|||
|
ITEM 1A
|
49
|
|||
|
ITEM 2
|
49
|
|||
|
ITEM 3
|
49
|
|||
|
ITEM 4
|
49
|
|||
|
ITEM 5
|
49
|
|||
|
ITEM 6
|
50
|
|||
|
51
|
||||
| ● |
declining sales of tobacco products, and expected continuing decline of sales, in the tobacco industry overall;
|
| ● |
our dependence on a small number of third-party suppliers and producers;
|
| ● |
the possibility that we will be unable to identify or contract with new suppliers or producers in the event of a supply or product disruption;
|
| ● |
the possibility that our licenses to use certain brands or trademarks will be terminated, challenged or restricted;
|
| ● |
failure to maintain consumer brand recognition and loyalty of our customers;
|
| ● |
our reliance on relationships with several large retailers and national chains for distribution of our products;
|
| ● |
uncertainty and continued evolution of markets containing our NewGen products;
|
| ● |
intense competition and our ability to compete effectively;
|
| ● |
competition from illicit sources;
|
| ● |
regulation of our products by the FDA, which has broad regulatory powers;
|
| ● |
our products are subject to developing and unpredictable regulation, for example, current court action moving forward certain substantial Pre Market Tobacco Application obligations;
|
| ● |
uncertainty related to the regulation and taxation of our NewGen products;
|
| ● |
possible significant increases in federal, state and local municipal tobacco- and vapor-related taxes;
|
| ● |
sensitivity of end-customers to increased sales taxes and economic conditions;
|
| ● |
substantial and increasing U.S. regulation;
|
| ● |
possible increasing international control and regulation;
|
| ● |
failure to comply with certain regulations;
|
| ● |
imposition of significant tariffs on imports into the U.S.;
|
| ● |
the scientific community’s lack of information regarding the long-term health effects of certain substances contained in some of our products;
|
| ● |
some of our products contain nicotine which is considered to be a highly addictive substance;
|
| ● |
contamination of our tobacco supply or products;
|
| ● |
requirement to maintain compliance with master settlement agreement escrow account;
|
| ● |
our amount of indebtedness;
|
| ● |
the terms of our credit facilities, which may restrict our current and future operations;
|
| ● |
significant product liability litigation;
|
| ● |
reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors, potentially decreasing our stock price;
|
| ● |
failure to maintain our status as an emerging growth company before the five-year maximum time period a company may retain such status;
|
| ● |
our principal stockholders will be able to exert significant influence over matters submitted to our stockholders and may take certain actions to prevent takeovers;
|
| ● |
our certificate of incorporation and bylaws, as well as Delaware law and certain regulations, could discourage or prohibit acquisition bids or merger proposals, which may adversely affect the market price of our common stock;
|
| ● |
our certificate of incorporation limits the ownership of our common stock by individuals and entities that are Restricted Investors. These restrictions may affect the liquidity of our common stock and may result in Restricted Investors being required to sell or redeem their shares at a loss or relinquish their voting, dividend and distribution rights;
|
| ● |
our business may be damaged by events outside of our suppliers’ control, such as the impact of epidemics (e.g., coronavirus), political upheavals, or natural disasters;
|
| ● |
our reliance on information technology;
|
| ● |
security and privacy breaches;
|
| ● |
infringement on our intellectual property;
|
| ● |
third-party claims that we infringe on their intellectual property;
|
| ● |
failure to manage our growth;
|
| ● |
failure to successfully integrate our acquisitions or otherwise be unable to benefit from pursuing acquisitions;
|
| ● |
fluctuations in our results;
|
| ● |
exchange rate fluctuations;
|
| ● |
adverse U.S. and global economic conditions;
|
| ● |
departure of key management personnel or our inability to attract and retain talent;
|
| ● |
future sales of our common stock in the public market could reduce our stock price, and any additional capital raised by us through the sale of equity or convertible securities may dilute your ownership in us; and
|
| ● |
we may issue preferred stock whose terms could adversely affect the voting power or value of our common stock.
|
|
ASSETS
|
(unaudited)
September 30,
2020
|
December 31,
2019
|
||||||
|
Current assets:
|
||||||||
|
Cash
|
$
|
|
$
|
|
||||
|
Accounts receivable, net of allowances of $
|
|
|
||||||
|
Inventories
|
|
|
||||||
|
Other current assets
|
|
|
||||||
|
Total current assets
|
|
|
||||||
|
Property, plant, and equipment, net
|
|
|
||||||
|
Right of use assets
|
|
|
||||||
|
Deferred financing costs, net
|
|
|
||||||
|
Goodwill
|
|
|
||||||
|
Other intangible assets, net
|
|
|
||||||
|
Master Settlement Agreement (MSA) escrow deposits
|
|
|
||||||
|
Other assets
|
|
|
||||||
|
Total assets
|
$
|
|
$
|
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
|
$
|
|
||||
|
Accrued liabilities
|
|
|
||||||
|
Current portion of long-term debt
|
|
|
||||||
|
Total current liabilities
|
|
|
||||||
|
Notes payable and long-term debt
|
|
|
||||||
|
Deferred income taxes
|
|
|
||||||
|
Lease liabilities
|
|
|
||||||
|
Other long-term liabilities
|
|
|
||||||
|
Total liabilities
|
|
|
||||||
|
Commitments and contingencies
|
|
|
||||||
|
Stockholders’ equity:
|
||||||||
|
Preferred stock; $
|
|
|
||||||
|
Common stock, voting,
$
|
|
|
||||||
|
Common stock, nonvoting, $
|
|
|
||||||
|
Additional paid-in capital
|
|
|
||||||
|
Cost of repurchased common stock
(
|
(
|
)
|
|
|||||
|
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
|
Accumulated earnings (deficit)
|
|
(
|
)
|
|||||
|
Total stockholders’ equity
|
|
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
||||
|
|
Three Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Net sales
|
$
|
|
$
|
|
||||
|
Cost of sales
|
|
|
||||||
|
Gross profit
|
|
|
||||||
|
Selling, general, and administrative expenses
|
|
|
||||||
|
Operating income
|
|
|
||||||
|
Interest expense, net
|
|
|
||||||
|
Investment income
|
(
|
)
|
(
|
)
|
||||
|
Loss on extinguishment of debt
|
|
|
||||||
|
Net periodic cost (income), excluding service cost
|
|
(
|
)
|
|||||
|
Income before income taxes
|
|
|
||||||
|
Income tax expense
|
|
|
||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||
|
Basic income per common share:
|
||||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||
|
Diluted income per common share:
|
||||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||
|
Weighted average common shares outstanding:
|
||||||||
|
Basic
|
|
|
||||||
|
Diluted
|
|
|
||||||
|
|
Nine Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Net sales
|
$
|
|
$
|
|
||||
|
Cost of sales
|
|
|
||||||
|
Gross profit
|
|
|
||||||
|
Selling, general, and administrative expenses
|
|
|
||||||
|
Operating income
|
|
|
||||||
|
Interest expense, net
|
|
|
||||||
|
Investment income
|
(
|
)
|
(
|
)
|
||||
|
Loss on extinguishment of debt
|
|
|
||||||
|
Net periodic cost (income), excluding service cost
|
|
(
|
)
|
|||||
|
Income before income taxes
|
|
|
||||||
|
Income tax expense
|
|
|
||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||
|
Basic income per common share:
|
||||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||
|
Diluted income per common share:
|
||||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||
|
Weighted average common shares outstanding:
|
||||||||
|
Basic
|
|
|
||||||
|
Diluted
|
|
|
||||||
|
|
Three Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||
|
Other comprehensive income, net of tax
|
||||||||
|
Amortization of unrealized pension and postretirement gain (loss), net of tax of $
|
|
(
|
)
|
|||||
|
Unrealized gain on investments, net of tax of $
|
|
|
||||||
|
Unrealized gain (loss) on derivative instruments, net of tax of $
|
|
(
|
)
|
|||||
|
|
|
|||||||
|
Consolidated comprehensive income
|
$
|
|
$
|
|
||||
|
|
Nine Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||
|
Other comprehensive income (loss), net of tax
|
||||||||
|
Amortization of unrealized pension and postretirement gain (loss), net of tax of
$
|
|
(
|
)
|
|||||
|
Unrealized gain on investments, net of tax of
$
|
|
|
||||||
|
Unrealized loss on derivative instruments, net of tax of
$
|
(
|
)
|
(
|
)
|
||||
|
|
(
|
)
|
||||||
|
Consolidated comprehensive income
|
$
|
|
$
|
|
||||
|
|
Nine Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
|
Loss on extinguishment of debt
|
|
|
||||||
|
Pension settlement and curtailment loss
|
|
|
||||||
|
Impairment loss
|
|
|
||||||
|
Loss (gain) on sale of property, plant, and equipment
|
|
(
|
)
|
|||||
|
Depreciation expense
|
|
|
||||||
|
Amortization of other intangible assets
|
|
|
||||||
|
Amortization of debt discount and deferred financing costs
|
|
|
||||||
|
Deferred income taxes
|
|
(
|
)
|
|||||
|
Stock compensation expense
|
|
|
||||||
|
Noncash lease expense
|
|
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
(
|
)
|
(
|
)
|
||||
|
Inventories
|
(
|
)
|
(
|
)
|
||||
|
Other current assets
|
(
|
)
|
(
|
)
|
||||
|
Other assets
|
|
|
||||||
|
Accounts payable
|
(
|
)
|
|
|||||
|
Accrued postretirement liabilities
|
(
|
)
|
(
|
)
|
||||
|
Accrued liabilities and other
|
|
(
|
)
|
|||||
|
Net cash provided by operating activities
|
$
|
|
$
|
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Capital expenditures
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
Acquisitions, net of cash acquired
|
(
|
)
|
(
|
)
|
||||
|
Restricted cash, MSA deposits
|
|
|
||||||
|
Proceeds on the sale of property, plant and equipment
|
|
|
||||||
|
Payments for investments
|
|
(
|
)
|
|||||
|
Net cash (used in) provided by investing activities
|
$
|
(
|
)
|
$
|
|
|||
|
Cash flows from financing activities:
|
||||||||
|
Payments of 2018 first lien term loan
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
Payments of 2018 second lien term loan
|
|
(
|
)
|
|||||
|
Payments of 2018 revolving credit facility
|
|
(
|
)
|
|||||
|
Proceeds from Convertible Senior Notes
|
|
|
||||||
|
Payment of IVG note
|
(
|
)
|
|
|||||
|
Proceeds from unsecured note
|
|
|
||||||
|
Standard Diversified Inc. reorganization, net of cash acquired
|
(
|
)
|
|
|||||
|
Payment for call options
|
|
(
|
)
|
|||||
|
Payment of dividends
|
(
|
)
|
(
|
)
|
||||
|
Payments of financing costs
|
(
|
)
|
(
|
)
|
||||
|
Exercise of options
|
|
|
||||||
|
Surrender of restricted stock
|
|
(
|
)
|
|||||
|
Redemption of options
|
|
(
|
)
|
|||||
|
Common stock repurchased
|
(
|
)
|
|
|||||
|
Net cash (used in) provided by financing activities
|
$
|
(
|
)
|
$
|
|
|||
|
Net (decrease) increase in cash
|
$
|
(
|
)
|
$
|
|
|||
|
Cash, beginning of period:
|
||||||||
|
Unrestricted
|
|
|
||||||
|
Restricted
|
|
|
||||||
|
Total cash at beginning of period
|
|
|
||||||
|
Cash, end of period:
|
||||||||
|
Unrestricted
|
|
|
||||||
|
Restricted
|
|
|
||||||
|
Total cash at end of period
|
$
|
|
$
|
|
||||
|
Supplemental schedule of noncash investing activities:
|
||||||||
|
Hold back for acquisition
|
$
|
|
$
|
|
||||
|
Supplemental schedule of noncash financing activities:
|
||||||||
|
Dividends declared not paid
|
$
|
|
$
|
|
||||
|
Issuance of note payable for acquisition
|
$
|
|
$
|
|
||||
|
Accrued expenses for incurred financing costs
|
$
|
|
$
|
|
||||
|
|
Voting
Shares
|
Common
Stock,
Voting
|
Additional
Paid-In
Capital
|
Cost of
Repurchased
Common Stock
|
Accumulated
Other
Comprehensive
Loss
|
Accumulated
Earnings (Deficit)
|
Total
|
|||||||||||||||||||||
|
Beginning balance July 1, 2020
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||
|
Unrecognized pension and postretirement cost adjustment, net of tax of $
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Unrealized gain on derivative instruments, net of tax of $
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Stock compensation expense
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Exercise of options
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Cost of repurchased common stock
|
(
|
)
|
|
|
(
|
)
|
|
|
(
|
)
|
||||||||||||||||||
|
Standard Diversified Inc. reorganization, net
|
(
|
)
|
(
|
)
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||
|
Dividends
|
-
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Net income
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Ending balance September 30, 2020
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
|||||||||||||
|
Beginning balance July 1, 2019
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||||
|
Unrecognized pension and postretirement cost adjustment, net of tax of $
|
-
|
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||
|
Unrealized gain on MSA investments, net of tax of $
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Unrealized loss on derivative instruments, net of tax of $
|
-
|
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||
|
Stock compensation expense
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Restricted stock forfeitures
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Exercise of options
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Dividends
|
-
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Purchase of call options, net of tax of $
|
-
|
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||||||||
|
Issuance of Convertible Senior Notes, net of tax of $
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Net income
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Ending balance September 30, 2019
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||||
|
|
Voting
Shares
|
Common
Stock,
Voting
|
Additional
Paid-In
Capital
|
Cost of
Repurchased
Common Stock
|
Accumulated
Other
Comprehensive
Loss
|
Accumulated
Earnings (Deficit)
|
Total
|
|||||||||||||||||||||
|
Beginning balance January 1, 2020
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||||
|
Unrecognized pension and postretirement cost adjustment, net of tax of $
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Unrealized loss on derivative instruments, net of tax of $
|
-
|
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||
|
Stock compensation expense
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Exercise of options
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Cost of repurchased common stock
|
(
|
)
|
|
|
(
|
)
|
|
|
(
|
)
|
||||||||||||||||||
|
Standard Diversified Inc. reorganization, net
|
(
|
)
|
(
|
)
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||
|
Dividends
|
-
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Net income
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Ending balance September 30, 2020
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
|||||||||||||
|
Beginning balance January 1, 2019
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||||
|
Unrecognized pension and postretirement cost adjustment, net of tax of $
|
-
|
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||
|
Unrealized gain on MSA investments, net of tax of $
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Unrealized loss on derivative instruments, net of tax of $
|
-
|
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||
|
Stock compensation expense
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Restricted stock forfeitures
|
(
|
)
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||||||||
|
Exercise of options
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Redemption of options
|
-
|
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||||||||
|
Dividends
|
-
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Purchase of call options, net of tax of $
|
-
|
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||||||||
|
Issuance of Convertible Senior Notes, net of tax of $
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Net income
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Ending balance September 30, 2019
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||||
| ● |
Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets at the measurement date.
|
| ● |
Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
|
| ● |
Level 3 – Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
|
|
|
Deposits as of
|
|||||||
|
Sales
Year
|
September 30,
2020
|
December 31,
2019
|
||||||
|
1999
|
$
|
|
$
|
|
||||
|
2000
|
|
|
||||||
|
2001
|
|
|
||||||
|
2002
|
|
|
||||||
|
2003
|
|
|
||||||
|
2004
|
|
|
||||||
|
2005
|
|
|
||||||
|
2006
|
|
|
||||||
|
2007
|
|
|
||||||
|
2008
|
|
|
||||||
|
2009
|
|
|
||||||
|
2010
|
|
|
||||||
|
2011
|
|
|
||||||
|
2012
|
|
|
||||||
|
2013
|
|
|
||||||
|
2014
|
|
|
||||||
|
2015
|
|
|
||||||
|
2016
|
|
|
||||||
|
2017
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
Total consideration transferred
|
$
|
|
||
|
Adjustments to consideration transferred:
|
||||
|
Cash acquired
|
(
|
)
|
||
|
Working capital
|
(
|
)
|
||
|
Adjusted consideration transferred
|
|
|||
|
Assets acquired:
|
||||
|
Working capital (primarily AR and inventory)
|
|
|||
|
Fixed assets and Other long term assets
|
|
|||
|
Intangible assets
|
|
|||
|
Other liabilities
|
(
|
)
|
||
|
Net assets acquired
|
$
|
|
||
|
Goodwill
|
$
|
|
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
Raw materials and work in process
|
$
|
|
$
|
|
||||
|
Leaf tobacco
|
|
|
||||||
|
Finished goods - Smokeless products
|
|
|
||||||
|
Finished goods - Smoking products
|
|
|
||||||
|
Finished goods - NewGen products
|
|
|
||||||
|
Other
|
|
|
||||||
|
Gross Inventory
|
|
|
||||||
|
LIFO reserve
|
(
|
)
|
(
|
)
|
||||
|
Net Inventory
|
$
|
|
$
|
|
||||
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
Inventory deposits
|
$
|
|
$
|
|
||||
|
Insurance deposit
|
|
|
||||||
|
Prepaid taxes
|
|
|
||||||
|
Other
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
Land
|
$
|
|
$
|
|
||||
|
Buildings and improvements
|
|
|
||||||
|
Leasehold improvements
|
|
|
||||||
|
Machinery and equipment
|
|
|
||||||
|
Furniture and fixtures
|
|
|
||||||
|
Gross property, plant and equipment
|
|
|
||||||
|
Accumulated depreciation
|
(
|
)
|
(
|
)
|
||||
|
Net property, plant and equipment
|
$
|
|
$
|
|
||||
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
Equity investments
|
$
|
|
$
|
|
||||
|
Pension assets
|
|
|
||||||
|
Other
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
Accrued payroll and related items
|
$
|
|
$
|
|
||||
|
Customer returns and allowances
|
|
|
||||||
|
Taxes payable
|
|
|
||||||
|
Lease liabilities
|
|
|
||||||
|
Accrued interest
|
|
|
||||||
|
Other
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
2018 First Lien Term Loan
|
$
|
|
$
|
|
||||
|
Convertible Senior Notes
|
|
|
||||||
|
Note payable - Promissory Note
|
|
|
||||||
|
Note payable - Unsecured Loan
|
|
|
||||||
|
Note payable - IVG
|
|
|
||||||
|
Gross notes payable and long-term debt
|
|
|
||||||
|
Less deferred finance charges
|
(
|
)
|
(
|
)
|
||||
|
Less debt discount
|
(
|
)
|
(
|
)
|
||||
|
Less current maturities
|
(
|
)
|
(
|
)
|
||||
|
Notes payable and long-term debt
|
$
|
|
$
|
|
||||
|
|
Three Months Ended September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Operating lease cost
|
||||||||
|
Cost of sales
|
$
|
|
$
|
|
||||
|
Selling, general and administrative
|
|
|
||||||
|
Variable lease cost (1)
|
|
|
||||||
|
Short-term lease cost
|
|
|
||||||
|
Sublease income
|
(
|
)
|
(
|
)
|
||||
|
Total
|
$
|
|
$
|
|
||||
| (1) |
|
|
|
Nine Months Ended September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Operating lease cost
|
||||||||
|
Cost of sales
|
$
|
|
$
|
|
||||
|
Selling, general and administrative
|
|
|
||||||
|
Variable lease cost (1)
|
|
|
||||||
|
Short-term lease cost
|
|
|
||||||
|
Sublease income
|
(
|
)
|
(
|
)
|
||||
|
Total
|
$
|
|
$
|
|
||||
| (1) |
|
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
Assets:
|
||||||||
|
Right of use assets
|
$
|
|
$
|
|
||||
|
Total lease assets
|
$
|
|
$
|
|
||||
|
Liabilities:
|
||||||||
|
Current lease liabilities (2)
|
$
|
|
$
|
|
||||
|
Long-term lease liabilities
|
|
|
||||||
|
Total lease liabilities
|
$
|
|
$
|
|
||||
| (2) |
|
|
|
As of September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Weighted-average remaining lease term - operating leases
|
|
|
||||||
|
Weighted-average discount rate - operating leases
|
|
%
|
|
%
|
||||
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
2020
|
$
|
|
$
|
|
||||
|
2021
|
|
|
||||||
|
2022
|
|
|
||||||
|
2023
|
|
|
||||||
|
2024
|
|
|
||||||
|
Years thereafter
|
|
|
||||||
|
Total lease payments
|
$
|
|
$
|
|
||||
|
Less: Imputed interest
|
|
|
||||||
|
Present value of lease liabilities
|
$
|
|
$
|
|
||||
|
|
Three Months Ended September 30,
|
|||||||||||||||
|
Pension
Benefits
|
Postretirement
Benefits
|
|||||||||||||||
|
2020
|
2019
|
2020
|
2019
|
|||||||||||||
|
Service cost
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Interest cost
|
|
|
|
|
||||||||||||
|
Expected return on plan assets
|
|
(
|
)
|
|
|
|||||||||||
|
Amortization of (gains) losses
|
|
|
|
(
|
)
|
|||||||||||
|
Settlement and curtailment loss
|
|
|
|
|
||||||||||||
|
Net periodic benefit cost (income)
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
|||||||
|
|
Nine Months Ended September 30,
|
|||||||||||||||
|
Pension
Benefits
|
Postretirement
Benefits
|
|||||||||||||||
|
2020
|
2019
|
2020
|
2019
|
|||||||||||||
|
Service cost
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Interest cost
|
|
|
|
|
||||||||||||
|
Expected return on plan assets
|
(
|
)
|
(
|
)
|
|
|
||||||||||
|
Amortization of (gains) losses
|
|
|
(
|
)
|
(
|
)
|
||||||||||
|
Settlement and curtailment loss
|
|
|
|
|
||||||||||||
|
Net periodic benefit cost (income)
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||
|
|
Stock
Option
Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Grant Date
Fair Value
|
|||||||||
|
Outstanding, December 31, 2018
|
|
$
|
|
$
|
|
|||||||
|
Granted
|
|
|
|
|||||||||
|
Exercised
|
(
|
)
|
|
|
||||||||
|
Forfeited
|
(
|
)
|
|
|
||||||||
|
Outstanding, December 31, 2019
|
|
|
|
|||||||||
|
Granted
|
|
|
|
|||||||||
|
Exercised
|
(
|
)
|
|
|
||||||||
|
Forfeited
|
(
|
)
|
|
|
||||||||
|
Outstanding, September 30, 2020
|
|
$
|
|
$
|
|
|||||||
|
|
February 10,
2017
|
May 17,
2017
|
March 7,
2018
|
March 13,
2018
|
March 20,
2019
|
October 24,
2019
|
March 18,
2020
|
|||||||||||||||||||||
|
Number of options granted
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Options outstanding at September 30, 2020
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Number exercisable at September 30, 2020
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Exercise price
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||||
|
Remaining lives
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Risk free interest rate
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||||||||
|
Expected volatility
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||||||||
|
Expected life
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Dividend yield
|
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||||||||||
|
Fair value at grant date
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||||
|
|
March 31,
2017
|
March 7,
2018
|
March 20,
2019
|
March 20,
2019
|
July 19,
2019
|
March 18,
2020
|
||||||||||||||||||
|
Number of PRSUs granted
|
|
|
|
|
|
|
||||||||||||||||||
|
PRSUs outstanding at September 30, 2020
|
|
|
|
|
|
|
||||||||||||||||||
|
Fair value as of grant date
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
|
Remaining lives
|
|
|
|
-
|
|
|
||||||||||||||||||
|
|
Three Months Ended September 30,
|
|||||||||||||||||||||||
|
2020
|
2019
|
|||||||||||||||||||||||
|
Income
|
Shares
|
Per Share
|
Income
|
Shares
|
Per Share
|
|||||||||||||||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||||||||||||||||||
|
Basic EPS:
|
||||||||||||||||||||||||
|
Weighted average
|
|
$
|
|
|
$
|
|
||||||||||||||||||
|
Diluted EPS:
|
||||||||||||||||||||||||
|
Effect of dilutive securities:
|
||||||||||||||||||||||||
|
Stock options
|
|
|
||||||||||||||||||||||
|
|
$
|
|
|
$
|
|
|||||||||||||||||||
|
|
Nine Months Ended September 30,
|
|||||||||||||||||||||||
|
2020
|
2019
|
|||||||||||||||||||||||
|
Income
|
Shares
|
Per Share
|
Income
|
Shares
|
Per Share
|
|||||||||||||||||||
|
Consolidated net income
|
$
|
|
$
|
|
||||||||||||||||||||
|
Basic EPS:
|
||||||||||||||||||||||||
|
Weighted average
|
|
$
|
|
|
$
|
|
||||||||||||||||||
|
Diluted EPS:
|
||||||||||||||||||||||||
|
Effect of dilutive securities:
|
||||||||||||||||||||||||
|
Stock options
|
|
|
||||||||||||||||||||||
|
|
$
|
|
|
$
|
|
|||||||||||||||||||
|
|
Three Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Net sales
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
Gross profit
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
Operating income (loss)
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
(
|
)
|
|||||
|
Corporate unallocated
(1)
|
(
|
)
|
(
|
)
|
||||
|
Total
|
$
|
|
$
|
|
||||
|
Interest expense, net
|
|
|
||||||
|
Investment income
|
(
|
)
|
(
|
)
|
||||
|
Loss on extinguishment of debt
|
|
|
||||||
|
Net periodic cost (income), excluding service cost
|
|
(
|
)
|
|||||
|
Income before income taxes
|
$
|
|
$
|
|
||||
|
Capital expenditures
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
Depreciation and amortization
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
| (1) |
|
|
|
Nine Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Net sales
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
Gross profit
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
Operating income (loss)
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
(2)
|
|
|
||||||
|
Corporate unallocated
(1)
|
(
|
)
|
(
|
)
|
||||
|
Total
|
$
|
|
$
|
|
||||
|
Interest expense, net
|
|
|
||||||
|
Investment income
|
(
|
)
|
(
|
)
|
||||
|
Loss on extinguishment of debt
|
|
|
||||||
|
Net periodic cost (income), excluding service cost
|
|
(
|
)
|
|||||
|
Income before income taxes
|
$
|
|
$
|
|
||||
|
Capital expenditures
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
Depreciation and amortization
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
| (1) |
|
| (2) |
|
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
Assets
|
||||||||
|
Smokeless products
|
$
|
|
$
|
|
||||
|
Smoking products
|
|
|
||||||
|
NewGen products
|
|
|
||||||
|
Corporate unallocated
(1)
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
| (1) |
|
|
|
NewGen Segment
|
|||||||
|
Three Months Ended
September 30,
|
||||||||
|
2020
|
2019
|
|||||||
|
Business to Business
|
$
|
|
$
|
|
||||
|
Business to Consumer - Online
|
|
|
||||||
|
Business to Consumer - Corporate store
|
|
|
||||||
|
Other
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
|
NewGen Segment
|
|||||||
|
Nine Months Ended
September 30,
|
||||||||
|
2020
|
2019
|
|||||||
|
Business to Business
|
$
|
|
$
|
|
||||
|
Business to Consumer - Online
|
|
|
||||||
|
Business to Consumer - Corporate store
|
|
|
||||||
|
Other
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
|
Three Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Domestic
|
$
|
|
$
|
|
||||
|
Foreign
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
|
Nine Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Domestic
|
$
|
|
$
|
|
||||
|
Foreign
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
| • |
Our ability to further penetrate markets with our existing products;
|
| • |
Our ability to introduce new products and product lines that complement our core business;
|
| • |
Decreasing interest in some tobacco products among consumers;
|
| • |
Price sensitivity in our end-markets;
|
| • |
Marketing and promotional initiatives, which cause variability in our results;
|
| • |
General economic conditions, including consumer access to disposable income;
|
| • |
Cost and increasing regulation of promotional and advertising activities;
|
| • |
Cost of complying with regulation, including the “deeming regulations”;
|
| • |
Counterfeit and other illegal products in our end-markets;
|
| • |
Currency fluctuations;
|
| • |
Our ability to identify attractive acquisition opportunities in OTP; and
|
| • |
Our ability to integrate acquisitions.
|
|
|
Three Months Ended September 30,
|
|||||||||||
|
2020
|
2019
|
% Change
|
||||||||||
|
Consolidated Results of Operations Data:
|
||||||||||||
|
Net sales
|
||||||||||||
|
Smokeless products
|
$
|
29,764
|
$
|
26,187
|
13.7
|
%
|
||||||
|
Smoking products
|
35,973
|
30,222
|
19.0
|
%
|
||||||||
|
NewGen products
|
38,437
|
40,391
|
-4.8
|
%
|
||||||||
|
Total net sales
|
104,174
|
96,800
|
7.6
|
%
|
||||||||
|
Cost of sales
|
55,867
|
53,984
|
3.5
|
%
|
||||||||
|
Gross profit
|
||||||||||||
|
Smokeless products
|
16,042
|
13,587
|
18.1
|
%
|
||||||||
|
Smoking products
|
21,263
|
16,619
|
27.9
|
%
|
||||||||
|
NewGen products
|
11,002
|
12,610
|
-12.8
|
%
|
||||||||
|
Total gross profit
|
48,307
|
42,816
|
12.8
|
%
|
||||||||
|
Selling, general, and administrative expenses
|
32,286
|
29,784
|
8.4
|
%
|
||||||||
|
Operating income
|
16,021
|
13,032
|
22.9
|
%
|
||||||||
|
Interest expense, net
|
5,224
|
3,641
|
43.5
|
%
|
||||||||
|
Investment income
|
(3
|
)
|
(265
|
)
|
-98.9
|
%
|
||||||
|
Loss on extinguishment of debt
|
-
|
1,158
|
NM
|
|||||||||
|
Net periodic cost (income), excluding service cost
|
1,188
|
(12
|
)
|
NM
|
||||||||
|
Income before income taxes
|
9,612
|
8,510
|
12.9
|
%
|
||||||||
|
Income tax expense
|
1,816
|
2,236
|
-18.8
|
%
|
||||||||
|
Consolidated net income
|
$
|
7,796
|
$
|
6,274
|
24.3
|
%
|
||||||
|
|
Nine Months Ended September 30,
|
|||||||||||
|
2020
|
2019
|
% Change
|
||||||||||
|
Consolidated Results of Operations Data:
|
||||||||||||
|
Net sales
|
||||||||||||
|
Smokeless products
|
$
|
87,081
|
$
|
74,907
|
16.3
|
%
|
||||||
|
Smoking products
|
92,290
|
81,104
|
13.8
|
%
|
||||||||
|
NewGen products
|
120,455
|
125,756
|
-4.2
|
%
|
||||||||
|
Total net sales
|
299,826
|
281,767
|
6.4
|
%
|
||||||||
|
Cost of sales
|
161,996
|
157,304
|
3.0
|
%
|
||||||||
|
Gross profit
|
||||||||||||
|
Smokeless products
|
46,580
|
39,723
|
17.3
|
%
|
||||||||
|
Smoking products
|
53,066
|
43,841
|
21.0
|
%
|
||||||||
|
NewGen products
|
38,184
|
40,899
|
-6.6
|
%
|
||||||||
|
Total gross profit
|
137,830
|
124,463
|
10.7
|
%
|
||||||||
|
Selling, general, and administrative expenses
|
95,436
|
79,455
|
20.1
|
%
|
||||||||
|
Operating income
|
42,394
|
45,008
|
-5.8
|
%
|
||||||||
|
Interest expense, net
|
15,198
|
11,233
|
35.3
|
%
|
||||||||
|
Investment income
|
(128
|
)
|
(527
|
)
|
-75.7
|
%
|
||||||
|
Loss on extinguishment of debt
|
-
|
1,308
|
NM
|
|||||||||
|
Net periodic cost (income), excluding service cost
|
997
|
(34
|
)
|
NM
|
||||||||
|
Income before income taxes
|
26,327
|
33,028
|
-20.3
|
%
|
||||||||
|
Income tax expense
|
6,029
|
6,989
|
-13.7
|
%
|
||||||||
|
Consolidated net income
|
$
|
20,298
|
$
|
26,039
|
-22.0
|
%
|
||||||
|
(in thousands)
|
Three Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Consolidated net income
|
$
|
7,796
|
$
|
6,274
|
||||
|
Add:
|
||||||||
|
Interest expense, net
|
5,224
|
3,641
|
||||||
|
Loss on extinguishment of debt
|
-
|
1,158
|
||||||
|
Income tax expense
|
1,816
|
2,236
|
||||||
|
Depreciation expense
|
809
|
692
|
||||||
|
Amortization expense
|
477
|
356
|
||||||
|
EBITDA
|
$
|
16,122
|
$
|
14,357
|
||||
|
Components of Adjusted EBITDA
|
||||||||
|
Other (a)
|
1,188
|
151
|
||||||
|
Stock options, restricted stock, and incentives expense (b)
|
772
|
1,314
|
||||||
|
Transaction expenses (c)
|
570
|
470
|
||||||
|
New product launch costs (d)
|
-
|
1,979
|
||||||
|
FDA PMTA (e)
|
5,271
|
241
|
||||||
|
Corporate and vapor restructuring (f)
|
-
|
265
|
||||||
|
Adjusted EBITDA
|
$
|
23,923
|
$
|
18,777
|
||||
| (a) |
Represents LIFO adjustment, non-cash pension expense (income) and foreign exchange hedging.
|
| (b) |
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs.
|
| (c) |
Represents the fees incurred for transaction expenses.
|
| (d) |
Represents product launch costs for our new product lines.
|
| (e) |
Represents costs associated with applications related to FDA PMTA.
|
| (f) |
Represents costs associated with corporate and vapor restructuring including severance and inventory reserves.
|
|
(in thousands)
|
Nine Months Ended
September 30,
|
|||||||
|
2020
|
2019
|
|||||||
|
Consolidated net income
|
$
|
20,298
|
$
|
26,039
|
||||
|
Add:
|
||||||||
|
Interest expense, net
|
15,198
|
11,233
|
||||||
|
Loss on extinguishment of debt
|
-
|
1,308
|
||||||
|
Income tax expense
|
6,029
|
6,989
|
||||||
|
Depreciation expense
|
2,482
|
1,855
|
||||||
|
Amortization expense
|
1,304
|
1,079
|
||||||
|
EBITDA
|
$
|
45,311
|
$
|
48,503
|
||||
|
Components of Adjusted EBITDA
|
||||||||
|
Other (a)
|
841
|
(25
|
)
|
|||||
|
Stock options, restricted stock, and incentives expense (b)
|
1,987
|
3,227
|
||||||
|
Transaction expenses (c)
|
1,909
|
1,567
|
||||||
|
New product launch costs (d)
|
-
|
3,691
|
||||||
|
FDA PMTA (e)
|
14,435
|
241
|
||||||
|
Corporate and vapor restructuring (f)
|
-
|
1,419
|
||||||
|
Vendor settlement (g)
|
-
|
(5,522
|
)
|
|||||
|
Adjusted EBITDA
|
$
|
64,483
|
$
|
53,101
|
||||
| (a) |
Represents LIFO adjustment, non-cash pension expense (income) and foreign exchange hedging.
|
| (b) |
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs.
|
| (c) |
Represents the fees incurred for transaction expenses.
|
| (d) |
Represents product launch costs for our new product lines.
|
| (e) |
Represents costs associated with applications related to FDA PMTA.
|
| (f) |
Represents costs associated with corporate and vapor restructuring including severance and inventory reserves.
|
| (g) |
Represents costs associated with settlement of a vendor contract.
|
|
|
As of
|
|||||||
|
(in thousands)
|
September 30,
2020
|
December 31,
2019
|
||||||
|
Current assets
|
$
|
170,472
|
$
|
189,250
|
||||
|
Current liabilities
|
54,967
|
55,886
|
||||||
|
Working capital
|
$
|
115,505
|
$
|
133,364
|
||||
|
|
September 30,
2020
|
December 31,
2019
|
||||||
|
2018 First Lien Term Loan
|
$
|
138,000
|
$
|
146,000
|
||||
|
Convertible Senior Notes
|
172,500
|
172,500
|
||||||
|
Note payable - Promissory Note
|
10,000
|
-
|
||||||
|
Note payable - Unsecured Loan
|
7,485
|
-
|
||||||
|
Note payable - IVG
|
-
|
4,240
|
||||||
|
Gross notes payable and long-term debt
|
327,985
|
322,740
|
||||||
|
Less deferred finance charges
|
(5,360
|
)
|
(6,466
|
)
|
||||
|
Less debt discount
|
(26,833
|
)
|
(32,083
|
)
|
||||
|
Less current maturities
|
(12,000
|
)
|
(15,240
|
)
|
||||
|
Notes payable and long-term debt
|
$
|
283,792
|
$
|
268,951
|
||||
|
Period
|
Total Number
of Shares
Purchased
|
Average
Price Paid
per Share
|
Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
|
Maximum Number
(or Approximate
Dollar Value)
of Shares that
May Yet Be
Purchased Under the
Plans or Programs
|
||||||||||||
|
July 1 to July 31
|
-
|
$
|
-
|
-
|
44,710,727
|
|||||||||||
|
August 1 to August 31
|
52,630
|
$
|
28.97
|
52,630
|
43,186,036
|
|||||||||||
|
September 1 to September 30
|
29,467
|
$
|
28.91
|
29,467
|
42,334,145
|
|||||||||||
|
Total
|
82,097
|
82,097
|
||||||||||||||
|
Exhibit No.
|
Description
|
|
|
|
|
Agreement and Plan of Merger and Reorganization, dated as of April 7, 2020, by and among TPB, SDI and Merger Sub (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on April 8, 2020).
|
|
|
|
|
|
Turning Point Brands, Inc. Second Amended and Restated Bylaws.*
|
|
|
Release and Severance Agreement, dated August 19, 2020, by and among TPB and James W. Dobbins, Senior Vice President and General Counsel.*
|
|
|
|
|
|
Consulting Agreement dated August 19, 2020, but effective November 1, 2020, between Turning Point Brands, Inc. and James Dobbins*
|
|
|
|
|
|
Rule 13a-14(a)/15d-14(a) Certification of Lawrence S. Wexler.*
|
|
|
|
|
|
Rule 13a-14(a)/15d-14(a) Certification of Robert Lavan.*
|
|
|
|
|
|
Rule 13a-14(a)/15d-14(a) Certification of Brian Wigginton.*
|
|
|
|
|
|
Section 1350 Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
|
|
|
|
|
|
101
|
XBRL (eXtensible Business Reporting Language). The following materials from Turning Point Brands, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed on October 27, 2020, formatted in Inline XBRL (iXBRL): (i) consolidated balance sheets, (ii) consolidated statements of income, (iii) consolidated statements of comprehensive income, (iv) consolidated statements of cash flows, and (v) the notes to consolidated financial statements.*
|
|
|
|
|
104
|
Cover Page Interactive Data File (formatted in iXBRL and included in Exhibit 101).*
|
|
|
TURNING POINT BRANDS, INC.
|
|
||
|
|
|
|
|
|
|
|
|
By: /s/ Lawrence S. Wexler
|
|
|
|
|
|
Name: Lawrence S. Wexler
|
|
|
|
|
|
|
Title: President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
By: /s/ Robert Lavan
|
|
|
|
|
|
Name: Robert Lavan
|
|
|
|
|
|
|
Title: Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
By: /s/ Brian Wigginton
|
|
|
|
|
|
Name: Brian Wigginton
|
|
|
|
|
|
|
Title: Chief Accounting Officer
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|